| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Mental Health, Substance Use Disorder & I/DD Care for Central North Carolina Residents at Sandhills Center.
Since 1980, we have been offering our clients experienced and compassionate clinical care, which gives us the distinction of having served the people of Chesterfield longer than any other private mental health group practice in the county. Our staff of...
Emisphere Technologies, Inc. is a Cedar Knolls, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fluidx Medical Technologys novel GPX Embolic Device is a durable embolic that is easy to use, controllable, and effective for vessel occlusion.